Citizens JMP upgraded Spruce Biosciences (SPRB) to Outperform from Market Perform with a $254 price target The firm cites the company’s ...

Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.

Holding back tears, Christine Ulrich recalls how her daughter Veda once loved dancing, drawing and babbling. Now, she can no longer speak or even hold a crayon. Three years ago, Veda was diagnosed ...

Detailed price information for Spruce Biosciences Inc (SPRB-Q) from The Globe and Mail including charting and trades.

I started the Rare Dads RoundTables for fathers of special-needs children with rare diseases because I realized most dads don ...

Shares of Spruce Biosciences were lower after the company said it had agreed to sell shares in a private placement expected to raise $50 million in gross proceeds. The stock fell 23% to $140 in ...

The microcap biotech stock had its best day ever after the FDA granted its rare-disease drug a breakthrough designation.

Until now, Barth syndrome, a fatal genetic condition that affects the heart and muscles, was deemed untreatable. The first therapy has been greenlit by U.S. regulators, as it was able to improve ...

KNOXVILLE, Tenn. — Bryan and Blair Begbie said all they want for Rowan — their youngest daughter — is the chance to be a kid. However, the Food and Drug Administration issued what is called a Complete ...